PROM1 and osteosarcoma: Ni et al. developed salinomycin-loaded polymeric nanoparticles conjugated with CD133 aptamers (Ap-Sal-NP) to specifically target and destroy CD133+ osteosarcoma (Saos-2) cancer stem cells [217].